Entrada Therapeutics
TRDA on Nasdaq. Entrada Therapeutics develops genetic medicines for patients with neuromuscular and inherited retinal diseases. Market value $213m.
Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.
Should I look at this?
Not a fit for our list right now
Why it could be worth it
See Health care stocks that passed both tests
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $-62.97 of spare cash in the past 12 months. A savings account pays about $4.
The filings do not give us enough to work this out.
Each dollar kept in the business earns -46 cents a year. Above 10 is good.
Quality score: 34 of 100. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.
$5.48 a share, 6% above its 1-year low
Over the past year the price has ranged from $5.15 to $16.45.
Pays no dividend
Prices from Monday’s close (5 October).
Five years of cash, in billions
| Revenue | |||||
| Revenue | n/a | n/a | $129m | $211m | $25m |
| Operating margin | |||||
| Operating margin | n/a | n/a | -2.5% | 22.3% | -621.1% |
| Debt to equity | |||||
| Debt to equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Shares outstanding | |||||
| Shares outstanding | 0.03bn | 0.03bn | 0.04bn | 0.04bn | 0.04bn |
Health checks
- Free cash flow positive1 of 5 years
- Accounting checksSkipped: company is not yet profitable
- Debt0.00× equity
- Revenue growth, five yearsUnknown
- Buying back its own sharesNo, 24% more shares since 2021
The quarter to June 2026
How the business did, compared with the same quarter a year earlier.
- Sales: $898,000 last quarter, down 54% on a year ago.
- A loss of $43 million, compared with a loss of $43 million a year ago.
- It loses 3767 cents on each $1 of sales, compared with 121 cents a year earlier.
- Over the past 12 months it spent $134 million more cash than it brought in, compared with $127 million a year earlier.
- 2% more shares than a year ago. Each share owns a bit less of the company.
- It has $99 million more cash than debt, up from $72 million a year ago.
- Sales did not grow on a year ago in any of the last 4 quarters.
| Quarter to | Amount |
|---|---|
| September 2024 | $20m |
| December 2024 | $37m |
| March 2025 | $21m |
| June 2025 | $2m |
| September 2025 | $2m |
| December 2025 | $1m |
| March 2026 | $875,000 |
| June 2026 | $898,000 |
| Quarter to | Amount |
|---|---|
| September 2024 | -$14m |
| December 2024 | $1m |
| March 2025 | -$17m |
| June 2025 | -$43m |
| September 2025 | -$44m |
| December 2025 | -$39m |
| March 2026 | -$40m |
| June 2026 | -$43m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 26 February 2026
- Next quarterly (estimated, 10-Q)
- 4 November 2026
Who owns it
1 long-term investor we follow owns it, unchanged from 1 last quarter. 129 funds in all.
| Fund | Value | Share of that fund | Change |
|---|---|---|---|
| Royce & AssociatesChuck Royce | $610,159 | <0.1% | Cut |
Largest holders overall
- Baker Bros. Advisors LP$37m
- 5AM Venture Management$30m
- BlackRock$19mAdded
- Merck$13mNew
- Vanguard Capital Management$9m
- MPM Bioimpact$9mNew
- TCG Crossover Management$8mCut
- Wellington Management Group LLP$7mCut
- Millennium Management$6mAdded
- StepStone Group LP$6m
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
6 investors own more than 5%.
- Kush ParmarPassive investorat least 10.8%(filed with 6 related holders)Since 14 November 2025
- ANSBERT GADICKEPassive investorat least 9.9%(filed with 12 related holders)Since 8 September 2026
- Roche Finance LtdPassive investorat least 6.9%(filed with 1 related holder)Since 31 December 2024
- BlackRock, Inc.Passive investor5.3%Since 31 December 2024
- Janus Henderson Biotech Innovation Master Fund LtdPassive investor5.0%0.0 ptsSince 31 March 2025
- TCG Crossover GP I, LLCPassive investorat least 2.7%−2.3 pts(filed with 2 related holders)Since 30 June 2026
- JANUS HENDERSON GROUP PLCPassive investorSold down below 5%Since 30 June 2025
- T. Rowe Price Associates, Inc.Passive investorSold down below 5%Since 30 September 2025
| Holder | Stake | Since | |
|---|---|---|---|
Kush Parmar Passive investor | at least 10.8% (filed with 6 related holders) | 14 November 2025 | |
ANSBERT GADICKE Passive investor | at least 9.9% (filed with 12 related holders) | 8 September 2026 | |
Roche Finance Ltd Passive investor | at least 6.9% (filed with 1 related holder) | 31 December 2024 | |
BlackRock, Inc. Passive investor | 5.3% | 31 December 2024 | |
Janus Henderson Biotech Innovation Master Fund Ltd Passive investor | 5.0%0.0 pts | 31 March 2025 | |
TCG Crossover GP I, LLC Passive investor | at least 2.7%−2.3 pts (filed with 2 related holders) | 30 June 2026 | |
JANUS HENDERSON GROUP PLC Passive investor | Sold down below 5% | 30 June 2025 | |
T. Rowe Price Associates, Inc. Passive investor | Sold down below 5% | 30 September 2025 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 1 insider bought $29,300 of shares on the open market. 4 sold $5m, $1m of it under preset trading plans.
- PARMAR KUSHDirectorSold
- Date
- 10 August 2026
- Shares
- 92,444
- Price
- $7.00
- Value
- $647,108
- PARMAR KUSHDirectorSold
- Date
- 7 August 2026
- Shares
- 52,317
- Price
- $6.85
- Value
- $358,371
- PARMAR KUSHDirectorSold
- Date
- 6 August 2026
- Shares
- 10,494
- Price
- $7.00
- Value
- $73,458
- PARMAR KUSHDirectorSold
- Date
- 31 July 2026
- Shares
- 1,718
- Price
- $6.85
- Value
- $11,768
- PARMAR KUSHDirectorSold
- Date
- 30 July 2026
- Shares
- 114,756
- Price
- $6.93
- Value
- $795,259
- Zeiher Bernhardt GDirectorBought
- Date
- 20 May 2026
- Shares
- 5,000
- Price
- $5.86
- Value
- $29,300
- Sethuraman NatarajanPresident, Research & Develop.Soldunder a preset trading plan
- Date
- 4 May 2026
- Shares
- 25,907
- Price
- $15.39
- Value
- $398,709
- Dowden Nathan JPresident & COOSoldunder a preset trading plan
- Date
- 4 May 2026
- Shares
- 15,000
- Price
- $15.33
- Value
- $229,950
- WENTWORTH KORY JAMESChief Financial OfficerSoldunder a preset trading plan
- Date
- 1 April 2026
- Shares
- 2,500
- Price
- $12.95
- Value
- $32,375
- Dowden Nathan JPresident & COOSoldunder a preset trading plan
- Date
- 10 March 2026
- Shares
- 11,894
- Price
- $13.05
- Value
- $155,217
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 10 August 2026 | PARMAR KUSH Director | Sold | 92,444 | $7.00 | $647,108 |
| 7 August 2026 | PARMAR KUSH Director | Sold | 52,317 | $6.85 | $358,371 |
| 6 August 2026 | PARMAR KUSH Director | Sold | 10,494 | $7.00 | $73,458 |
| 31 July 2026 | PARMAR KUSH Director | Sold | 1,718 | $6.85 | $11,768 |
| 30 July 2026 | PARMAR KUSH Director | Sold | 114,756 | $6.93 | $795,259 |
| 20 May 2026 | Zeiher Bernhardt G Director | Bought | 5,000 | $5.86 | $29,300 |
| 4 May 2026 | Sethuraman Natarajan President, Research & Develop. | Sold under a preset trading plan | 25,907 | $15.39 | $398,709 |
| 4 May 2026 | Dowden Nathan J President & COO | Sold under a preset trading plan | 15,000 | $15.33 | $229,950 |
| 1 April 2026 | WENTWORTH KORY JAMES Chief Financial Officer | Sold under a preset trading plan | 2,500 | $12.95 | $32,375 |
| 10 March 2026 | Dowden Nathan J President & COO | Sold under a preset trading plan | 11,894 | $13.05 | $155,217 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
What could go wrong
Cheap for a reason is the question the numbers cannot answer.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.